All cancers start with mutated genes. Gene mutations can be inherited or can occur from environmental exposure. Studying genomics, genes, and gene function gives researchers and clinicians insight into how mutated genes impact cancer symptoms, tumor progression, treatment response, and health outcomes.
Cancer is reshaping our families, communities, and world. It is among the leading causes of death globally, and cancer rates are only increasing for nearly every age group and indication. Despite the prevalence of cancer, there is so much left to reveal. Download the handbook to learn what whole exome sequencing is, why it’s important, and how it’s furthering discoveries in cancer research.
Next generation sequencing (NGS) is a sequencing method that can provide valuable insight into cancer treatment and prevention. There are several approaches to using this technology for cancer research. Whole genome sequencing provides a comprehensive view of the genetic sequence of the sample, whether it be blood, tissue, or tumor. Targeted next generation sequencing focuses on specific areas of the genome that might be more relevant for cancer. For example, exome sequencing provides insight into protein-coding genes and is especially useful when evaluating mutation load. Hybridization capture panels can be customized to include nonprotein coding genes that might be relevant to a specific cancer like leukemia or breast cancer. NGS can include sequencing DNA or RNA. Because RNA can change the way proteins are expressed, RNA sequencing can also help researchers and clinicians learn more about cancer.
Hand-picked information on targeted sequencing in biomarker development and validation in cancer research.
Working in an area that would benefit from sequencing? Just starting? See how you can easily improve your workflows and results.
The xGen Exome Hyb Panel v2 is designed using a target-aware algorithm that reduces off-target binding while maximizing coverage. We manufacture this panel under ISO 13485 standards as a single large lot, promoting equal representation and consistency from one aliquot to the next.
The xGen Acute Myeloid Leukemia (AML) Cancer Panel v1.0 comprises 11,731 xGen Lockdown Probes, spanning 1.19 Mb of the human genome, for targeted enrichment of >260 genes associated with AML, to provide more efficient detection of disease-causing mutations.
The xGen Inherited Diseases Panel enables deeper sequencing of genomic regions containing genes and SNPs associated with inherited diseases. The gene list is based on the HGMD® (Human Gene Mutation Database) repository of known inherited disease-causing mutations.